Try our Advanced Search for more refined results
Health
-
April 20, 2026
High Court Won't Hear 3rd Circ. J&J Class Cert. Appeal
The U.S. Supreme Court on Monday said it won't review a class certification challenge in a securities class action over Johnson & Johnson's cancer-related talc products in the latest development in a closely watched dispute over how courts evaluate class certification in shareholder suits.
-
April 20, 2026
Justices Won't Consider IP Theft Allegations Against Akin
The U.S. Supreme Court on Monday rejected a former Cornell University graduate student's petition trying to revive his malpractice suit against Akin Gump Strauss Hauer & Feld LLP stemming from patent litigation against Illumina Inc. over DNA sequencing intellectual property.
-
April 17, 2026
ITC Clears Apple's Redesigned Apple Watch For Import
The U.S. International Trade Commission on Friday signed off on an administrative law judge's finding that Apple has sufficiently redesigned its smartwatch so it doesn't infringe Masimo Corp.'s patents and is therefore not bound by a 2023 import ban.
-
April 17, 2026
9th Circ. Revives Doctor's PeaceHealth Whistleblower Suit
A Ninth Circuit panel has reinstated a psychiatrist's claims that PeaceHealth Inc. retaliated against him for expressing concerns about potential Medicaid fraud at a Washington hospital, concluding on Friday that the district court overlooked evidence that the employer punished him by not renewing his employment contract.
-
April 17, 2026
Missed Deadline Fatal To Patient's Stapler Suit, 4th Circ. Says
The Fourth Circuit ruled Friday that a surgery patient's missed expert disclosure deadline rightfully ended his case seeking to hold Johnson & Johnson subsidiary Ethicon Endo-Surgery LLC liable for allegedly faulty staples used in his procedure.
-
April 17, 2026
Federal Judge Blocks DOJ's DEI, Citizenship Grant Conditions
A Rhode Island federal judge has temporarily blocked the U.S. Department of Justice from imposing new conditions related to diversity, equity and inclusion activities and immigration status on domestic violence assistance grants, finding a nonprofit coalition likely to succeed in a legal challenge.
-
April 17, 2026
Plea Change Hearing Set For Former Conn. Budget Official
A change of plea hearing has been scheduled for Monday afternoon for Konstantinos M. Diamantis, a former Connecticut budget official, elected politician and attorney facing an impending federal corruption trial for allegedly pocketing bribes while helping end a state Medicaid audit of an optometry practice operated by his friend's fiancée.
-
April 17, 2026
Connecticut Cardiologist Files $4M Suit Over Alleged Ouster
A Connecticut cardiologist alleges he suffered at least $4 million in damages due to his former practice's "repeated disrespect, bad faith" and reputational damage in the medical community for more than a decade, which culminated in his constructive discharge, filing a contract and defamation lawsuit in state court.
-
April 17, 2026
Judge Says USCIS Can't Keep Delaying Iranians' Work Permits
A California federal judge ordered U.S. Citizenship and Immigration Services to unfreeze its processing of work permit applications for several dozen Iranians and a Sudanese national, finding the agency likely violated federal administrative law by indefinitely delaying decisions.
-
April 17, 2026
Up Next At High Court: SEC And FCC Enforcement Authority
The U.S. Supreme Court's final argument session of this term kicks off Monday, when the justices will consider the U.S. Securities and Exchange Commission's authority to seek disgorgement orders against alleged wrongdoers without proving investors were harmed. Here, Law360 breaks down the week's oral arguments.
-
April 17, 2026
3 Key Questions On Trump's Pharma Tariffs
President Donald Trump recently announced 100% tariffs on certain imported pharmaceutical products, with opportunities for drug companies to lower their tariff rates to zero, but questions remain about the requirements for preferential treatment and abilities to administer the regime. Here, Law360 examines three open questions surrounding pharmaceutical tariffs' implementation.
-
April 17, 2026
Verdict For Doctors Affirmed In Fatal E. Coli Infection Appeal
An Illinois appellate panel on Friday affirmed a jury verdict clearing three physicians of liability in a wrongful death suit over a woman's death from septic shock stemming from an undiagnosed E. coli infection, rejecting arguments that evidentiary errors, expert testimony admissions and jury instruction issues warranted a new trial.
-
April 17, 2026
Allstate Says Fla. Surgery Centers Padded Bills For Care
Seven ambulatory surgery centers, a pain clinic and an anesthesia practice that are all run by Surgery Partners conducted "extraordinarily aggressive treatment" on patients involved in minor car crashes to inflate the bills submitted to Allstate, the insurer told a Florida federal court Friday, alleging it paid millions for unnecessary treatment.
-
April 17, 2026
AI Health Co. Illegally Shared Genetic Data, Patients Say
A healthcare company powered by artificial intelligence violated Illinois' genetic privacy law and other consumer protection laws by compelling a genetic testing business it acquired to disclose patients' genetic information, which it then shared through data agreements with pharmaceutical giants such as Eli Lilly and AbbVie, a lawsuit in Illinois federal court says.
-
April 17, 2026
Judge Says Biotech Co. Can't Wipe Cancer Data, For Now
A Texas state judge signed a temporary restraining order on Friday that stops Bellicum Pharmaceuticals Inc. and the consulting firm helping it oversee its dissolution from deleting cell therapy data that the Houston-based MD Anderson Cancer Center says belongs to it.
-
April 17, 2026
Bill Floated To Nix Medical Residency Antitrust Exemption
U.S. Sen. Mike Lee, R-Utah, has introduced legislation to repeal an antitrust exemption given to the medical residency matching program by Congress two decades ago, over concerns about wages and a bottleneck of medical school graduates.
-
April 17, 2026
Healthcare AI Co. Seeks to Drop 3 From Wage Suit
A data science platform said Friday that a former executive, who claims he was not paid after investing $750,000 into the business, cannot drag three out-of-state people loosely connected to the company into a North Carolina federal court and that key claims should be trimmed.
-
April 17, 2026
Aramark Joins NJ Insulin Pricing Suits Against PBMs
Aramark Services Inc. joined multidistrict litigation accusing CVS and pharmacy benefit managers of colluding to inflate the price of insulin.
-
April 17, 2026
Mich. Judge Strikes Pregnancy Limits On Advance Directives
A Michigan state judge struck down statutory rules barring providers from carrying out an incapacitated patient's advance directive to withdraw from life-sustaining treatment if the patient is pregnant, finding they violate reproductive rights enshrined in the state's constitution.
-
April 17, 2026
Latham Leads Kailera's $625M IPO In Obesity Drug Push
Obesity biotech Kailera Therapeutics made its public debut Friday, raising $625 million in an upsized initial public offering that represents one of the largest biotech IPOs in recent years.
-
April 17, 2026
Doc Says Texas Man Can't Sue Over Mailed Abortion Pills
A Texas man suing his ex-girlfriend's out-of-state doctor for prescribing mail-order abortion pills can't prove that the doctor caused the wrongful death of their unborn child, the doctor told a federal court, saying the case should be dismissed because he's not responsible for the woman's actions.
-
April 17, 2026
UK Litigation Roundup: Here's What You Missed In London
The past week in London has seen Aston Martin file an appeal in a row with Chinese carmaker Geely over its winged logo for London black cabs, Ineos sue Ben Ainslie's America's Cup team for a £180 million ($244 million) boat, White & Case face a claim from two energy storage companies, and a golf tour company bring a claim against Saudi Arabia's sovereign wealth fund after the fund invested in its rival.
-
April 17, 2026
Fed. Circ. Reverses $18M Penile Implant Trade Secret Win
In a unanimous precedential decision, the Federal Circuit on Friday largely reversed a California jury's $18.3 million trade secret verdict over a penile implant, holding that the asserted secrets were already publicly disclosed or generally known and therefore not protectable.
-
April 16, 2026
2nd Circ. Says Animal Groups Can't Challenge Swine Rule
The Second Circuit on Thursday held that a trio of animal welfare groups don't have the standing to fight the U.S. Department of Agriculture's revised practices for inspecting pigs at slaughterhouses, ruling that none of the groups have shown they are likely to be harmed by the rule.
-
April 16, 2026
Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief
President Donald Trump on Thursday nominated Dr. Erica Schwartz, a retired rear admiral who served in the U.S. Coast Guard and as deputy surgeon general in the first Trump administration, to be the Centers for Disease Control and Prevention's next director.
Expert Analysis
-
What We Know About DOJ's New FCA Enforcement Priorities
Recent remarks from the leader of the Justice Department’s commercial litigation branch provide key insights on how False Claims Act cases — especially healthcare fraud, trade fraud, antidiscrimination and cybersecurity claims — will be evaluated, prioritized and pursued as heightened enforcement becomes the new normal, say attorneys at Latham.
-
The Benefits Of Choosing A Niche Practice In The AI Age
As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.
-
How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.
-
How To Engage With Gov't's Direct-To-Consumer Drug Policy
The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.
-
Opinion
It's Time To Clarify California's Elder Abuse Act
As California's elderly population soars, the Golden State's high court and Legislature must provide needed clarification about the scope of the Elder Abuse Act, to resolve the inconsistencies and ambiguities that have impeded the law's ability to remedy elder abuse, neglect and abandonment, say attorneys at Horvitz & Levy.
-
Series
Podcasting Makes Me A Better Lawyer
Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.
-
When Fraud Involvement Disqualifies FCA Whistleblowers
A Massachusetts federal court's recent dismissal of a False Claims Act relator in U.S. ex rel. Perry v. First Psychiatric Planners provides instructive insight into when whistleblowers may be denied their share of settlement proceeds, even if their involvement in the underlying fraud is a step removed, say attorneys at Holland & Knight.
-
Job Shift Accommodation Ruling Clarifies 'Essential Function'
In Siebrecht v. Mercy Health-Iowa, the Eighth Circuit's recent denial of a disabled worker's shift exemption request shows that the essential function of a job can encompass more than core job requirements and include things like scheduling flexibility, says Kim Kirn at Miles Mediation & Arbitration.
-
Opinion
Fed. Circ. Must Bury Design Patent Doctrinal Zombies
After recently finding noninfringement in Range of Motion Products v. Armaid, the Federal Circuit must rehear the case to confront two troublesome doctrines of design patent law claim construction — feature filtration and claim verbalization — that have lingered for decades and intensified in recent years, say attorneys at McAndrews Held.
-
H-1B Registration Tips For New Wage-Weighted Selection
Practitioners participating in this year’s H-1B visa registration, currently underway, must understand that under the new wage-weighted selection process that replaced the random lottery, the crucial first step is choosing the correct standard occupational classification, says Jimmy Lai at Lai & Turner.
-
Lessons From Justices' Split On Major Questions Doctrine
The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.
-
Drug Wholesaler's DPA Shows Imperfect Efforts Still Count
Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.
-
Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot
The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.
-
Why Mukherji Won't End USCIS' EB-1A Two-Step
A Nebraska federal court's recent decision in Mukherji v. Miller seemed to vindicate longstanding complaints about the U.S. Citizenship and Immigration Services' controversial two-step adjudication process, declaring the framework unlawful — but Mukherji is unlikely to be the death blow that immigration practitioners have hoped for, says Jun Li at Reid & Wise.
-
Unique Issues Facing Brand-Compounder Patent Litigation
Recent litigation and potential enforcement action against Hims & Hers Health raise questions about how compounders and branded pharmaceuticals companies would be positioned in patent litigation as compared to generics companies, which would require strategies different from those that would be used in traditional Hatch-Waxman Act litigation, say attorneys at Morgan Lewis.